Literature DB >> 3816920

Inhibition of thrombocyte aggregation by oral motapizone and other drugs.

V Schulz, W Fischer, U Hanselle, W Huhmann, V Zietsch.   

Abstract

Ten healthy subjects took single oral doses of placebo, 8.8 +/- 1.8 mg motapizone, 40 +/- 13 mg captopril, 25 mg dihydralazine, 20 mg nifedipine and 4.5 +/- 1.1 mg prazosin in random order, and, as the last preparation 500 mg acetylsalicylic acid. Thrombocyte aggregation induced "ex-vivo" with collagen, ADP and adrenaline was measured before and after 60 min. Immediately before each dose, the "threshold concentration" of each agent was determined in each subject, i.e. the concentration producing about 90% of maximal aggregation. After the preparation had been taken, aggregation was induced with 1-, 2- and 4-times the threshold concentration. Both motapizone and also acetylsalicylic acid caused marked inhibition of aggregation at up to 4-times the threshold concentration; the dose ratio was about 1:50. Motapizone produced greater inhibition of the aggregation induced by ADP and acetylsalicylic acid than of that due to collagen. The inhibitory actions after captopril, dihydralazine, nifedipine and prazosin were weak and did not significantly differ from placebo.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3816920     DOI: 10.1007/bf00613515

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  17 in total

Review 1.  Pharmacological control of platelet and red blood cell function in the microcirculation.

Authors:  F De Clerck; J L David
Journal:  J Cardiovasc Pharmacol       Date:  1981 Nov-Dec       Impact factor: 3.105

2.  A pharmacological approach to the inhibition of platelet adhesion and platelet aggregation. Wright-Schulte Lecture.

Authors:  M Verstraete
Journal:  Haemostasis       Date:  1982

3.  Standardization of collagen: consideration of current practices in testing collagen-induced aggregation.

Authors:  M A Packham
Journal:  Thromb Haemost       Date:  1984-12-29       Impact factor: 5.249

4.  [Inhibition of platelet aggregation and thromboxane formation by the calcium antagonist nisoldipine following a single oral dose of 10 mg. A double-blind study in healthy probands].

Authors:  K Schrör; G Latta; H Darius; W Klaus; R Ziegler
Journal:  Klin Wochenschr       Date:  1985-01-02

5.  Cyclooxygenase inhibition, platelet function, and metabolite formation during chronic sulfinpyrazone dosing.

Authors:  A K Pedersen; G A FitzGerald
Journal:  Clin Pharmacol Ther       Date:  1985-01       Impact factor: 6.875

6.  Time and temperature dependent changes of ADP - and collagen-induced and "spontaneous" aggregation.

Authors:  K Breddin; M Ziemen; O Bauer; W Herrmann; L Schaudinn; U Schlosser; A Winterhagen; H J Krzywanek
Journal:  Thromb Res       Date:  1980 Aug 15-Sep 1       Impact factor: 3.944

7.  Aspirin kinetics and platelet aggregation in man.

Authors:  D J Siebert; F Bochner; D M Imhoff; S Watts; J V Lloyd; J Field; B W Gabb
Journal:  Clin Pharmacol Ther       Date:  1983-03       Impact factor: 6.875

8.  Sources of variability in dose response platelet aggregometry.

Authors:  M V Vickers; S G Thompson
Journal:  Thromb Haemost       Date:  1985-04-22       Impact factor: 5.249

9.  Monitoring the entry of new platelets into the circulation after ingestion of aspirin.

Authors:  G Di Minno; M J Silver; S Murphy
Journal:  Blood       Date:  1983-06       Impact factor: 22.113

10.  Suppressive effect of captopril on platelet aggregation in essential hypertension.

Authors:  N Someya; Y Morotomi; K Kodama; O Kida; T Higa; K Kondo; K Tanaka
Journal:  J Cardiovasc Pharmacol       Date:  1984 Sep-Oct       Impact factor: 3.105

View more
  1 in total

1.  Hypotensive and antiplatelet actions of motapizone depend on dose and time after ingestion.

Authors:  V Schulz; W Fischer; U Hanselle; W Huhmann; V Zietsch
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.